Ibogaine Treatment for
Polysubstance Addiction

Comprehensive Assessment

Full evaluation of every substance you use — type, dose, frequency, duration, and route of administration. Psychiatric screening, cardiac evaluation, liver function, and complete medication review. This is the most thorough intake of any treatment you have experienced, because it has to be. Every substance combination creates specific considerations that must be accounted for in your protocol.

Pre-Treatment Preparation

Any substances that require tapering (benzodiazepines, certain psychiatric medications) are managed on a physician-supervised timeline. Methadone patients complete our bridging protocol. Stimulant-using patients receive cardiovascular stabilization assessment. This phase may take days to weeks depending on your specific combination — we give you an honest timeline during intake.

Arrival & Stabilization

Private transfer to our Cozumel facility. Initial days dedicated to physiological stabilization, nutritional support, sleep restoration, and beginning the TA booster phase. Polysubstance patients often arrive in states of significant physical depletion — we address these foundations systematically before the treatment session.

Treatment Protocol

A 12-18 day individualized program with TA booster dosing, HCl flood session under continuous 24/7 physician supervision with cardiac monitoring, and daily integration sessions with our clinical team. The protocol is calibrated to your specific substance combination. The treatment addresses the shared neurological substrate of all substances simultaneously.

Integration & Aftercare

90-day structured integration beginning at discharge. For polysubstance patients, aftercare includes substance-specific relapse prevention strategies, continued taper support for any remaining medications, and scheduled follow-ups to monitor recovery across all substance domains. The neuroplastic window following ibogaine is the opportunity to rebuild — our aftercare ensures it is used.

Yes. Ibogaine's multi-receptor mechanism is why it is uniquely suited to polysubstance use. Unlike medications designed for a single receptor system (naltrexone for opioids, disulfiram for alcohol), ibogaine simultaneously modulates opioid receptors, NMDA receptors, serotonin transporters, sigma-2 receptors, and dopaminergic pathways. This means it addresses the neurochemical disruption caused by opioids, stimulants, alcohol, and their combinations in a single treatment session. Our clinical experience with polysubstance patients consistently shows improvement across all substances, not just the primary one.

The most common polysubstance presentations at MindScape are: opioids plus methamphetamine (speedballing or alternating use), opioids plus benzodiazepines (frequently co-prescribed or co-used), opioids plus alcohol, stimulants plus alcohol, and combinations involving three or more substances. We also frequently see patients using kratom, gabapentin, or prescription stimulants alongside their primary addiction. Each combination requires specific protocol considerations, and our medical director designs individualized treatment plans based on the exact substances, doses, and durations involved.

It requires more careful pre-treatment preparation, but ibogaine treatment itself is not inherently more dangerous for polysubstance patients when screening is thorough. The complexity lies in the pre-treatment phase: managing tapers for multiple medications, assessing cardiac risk from stimulant use, evaluating liver function compromised by alcohol, and ensuring complete clearance of substances that interact dangerously with ibogaine. This is why our screening process is extensive — we do not cut corners. The treatment itself addresses the shared neurological substrate of addiction regardless of how many substances are involved.

Our urine drug screen (10-panel minimum) will identify most substances, including some patients may have forgotten or not considered relevant. But the screen is not a substitute for honest disclosure — some substances (kratom, certain research chemicals, supplements) may not appear on standard panels. We create a zero-judgment environment for this conversation. Our medical team has heard every combination and every circumstance. Incomplete disclosure is the single greatest safety risk we encounter. Tell us everything, and we can keep you safe.

Typically 12-18 days, depending on the substances involved and the pre-treatment preparation required. Patients on methadone require a bridging protocol before ibogaine. Patients with significant benzodiazepine use need tapering time. Stimulant-using patients need cardiovascular stabilization. The ibogaine treatment session itself is the same duration regardless of substance count — what changes is the preparation and the integration framework afterward. Our team gives you a specific timeline during intake based on your individual situation.

This is the critical distinction. Polysubstance use almost always reflects an attempt to manage an unresolved underlying condition — trauma, chronic pain, untreated mental health disorders, or a nervous system that has been in survival mode for years. Different substances serve different functions: opioids for pain and emotional numbing, stimulants for energy and escape from depression, alcohol for social anxiety and sleep, benzodiazepines for hypervigilance. Ibogaine's extended introspective experience, combined with our integration therapy, gives patients access to these root patterns. When the underlying driver is addressed, the need for the entire substance portfolio diminishes.